Article
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Cancer discovery - 1 Oct 2014
Van Allen Eliezer M, Mouw Kent W, Kim Philip, Iyer Gopa, Wagle Nikhil, Al-Ahmadie Hikmat, Zhu Cong, Ostrovnaya Irina, Kryukov Gregory V, O'Connor Kevin W, Sfakianos John, Garcia-Grossman Ilana, Kim Jaegil, Guancial Elizabeth A, Bambury Richard, Bahl Samira, Gupta Namrata, Farlow Deborah, Qu Angela, Signoretti Sabina, Barletta Justine A, Reuter Victor, Boehm Jesse, Lawrence Michael, Getz Gad, Kantoff Philip, Bochner Bernard H, Choueiri Toni K, Bajorin Dean F, Solit David B, Gabriel Stacey, D'Andrea Alan, Garraway Levi A, Rosenberg Jonathan E
Abstract excerpt
UNLABELLED: Cisplatin-based chemotherapy is the standard of care for patients with muscle-invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely understood. We performed whole-exome sequencing on pretreatment tumor and germline DNA from 50 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.